The exclusion footnote is a real disclosure
Both product pages carry the same paragraph directly beneath the price: the service is not available to residents of three named states, the figure covers the consultation plus the medication if prescribed, not all patients will be eligible, and no medication is dispensed without provider approval.
That is four separate conditions published in the place they belong, under the number they qualify. Most sellers here put the eligibility language on a legal page and the price on a marketing page and let the reader assume they meet.
It also happens to be a rendered paragraph rather than something buried in a data payload, which matters because this site hides more than it shows: the priced pages extract to roughly four thousand characters and the FAQ answers sit behind controls that do not render.
And the telemedicine policy contradicts it
The policy carries a section headed state availability. It says the company currently operates in select states where its providers are licensed, that a list of available states is provided at the time of registration and may be updated periodically, that some states require a video consultation before a prescription, and that certain medications may be unavailable in some states.
Read that against the price footnote and the two do not describe the same footprint. One is an exclusion of three, which implies the rest. The other is an allowlist that exists but is not published.
So our record carries no states for this seller and says why. Fifty-eight of the ninety-five sellers here publish no service area at all; this one publishes two, and they disagree. Deriving a number from the exclusion while the allowlist sentence sits on the same site would be inventing a list the seller declined to publish.
Both prices are discounts against an anchor, with no term
Each product card prints a struck-through figure and a lower one, on the same line, with no plan length between them. Nothing on either page says whether the lower figure is a first fill, a monthly rate, a prepayment or an introductory price.
The footnote answers a different question — what the figure covers — rather than the one a buyer needs, which is how long it lasts. There is no plan selector on the page and no ladder.
That is why this row does not score for price stability. A discount off an anchor with no term is not an ongoing rate, and this site never says what the ongoing rate is.
The membership question is not answered at all
We looked for it properly rather than assuming. The word membership returns zero matches in the extracted visible text of six pages: the homepage, both compounded product pages, the Terms of Service, the Privacy Policy and the telemedicine policy.
The nearest thing to an answer is the price footnote saying the figure reflects the consultation plus the medication if prescribed. That describes what the number covers. It does not say whether a separate programme fee exists.
Twenty-five of the ninety-five sellers here say nothing either way about a membership or programme fee, and this is one of them. This roster records a membership as absent only when a seller says so, never when it merely omits it.
An entity, a clinical vendor, and no people
The Terms name the operating company in the first sentence, which is a clean disclosure and more than several sellers here manage. The telemedicine policy names the clinical entity that provides the consultations, separately, with a version number and a dated effective line.
No individual clinician appears anywhere. No pharmacy is named — and the site's own FAQ asks whether it uses FDA-regulated pharmacies, then puts the answer behind a control that does not render. A question the seller thought worth asking, answered where a reader cannot see it, is a particular kind of gap.
Sixty-nine of the ninety-five sellers here name no compounding pharmacy, and fifty-one name nobody who prescribes. This row is in both groups, with the added wrinkle that it raises the pharmacy question itself.
What the pages do publish about quality is unusually precise: batch testing on a stated schedule for concentration within a stated tolerance, pH, sterility to a named chapter of the pharmacopoeia, and an endotoxin threshold to another. Citing the chapters by number is better practice than the vague accreditation language most of this field uses.
RxION Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/moPrinted as a discount off a struck anchor with no term stated: "Starting at $199 $99/month". The footnote directly beneath is a coverage statement, not a price condition: "Not available for residents of New Jersey, Alaska or Mississippi. Price reflects consultation plus medication if prescribed. Not all patients will be eligible. No medication is dispensed without provider approval." | September 2026source |
| Tirzepatide (compounded) | $183/moSame shape as the semaglutide card: "Starting at $299 $183/month", with the identical exclusion footnote beneath it. ⚠ Neither card names a plan length, a dose, or what happens after the first month. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 95 providers reviewed here are paid partners today; the other 91 are not. See how this works.
See RxION Health's current price →Good fit if
- Readers who want the state exclusions printed under the price rather than discovered at intake.
- Buyers who want the figure stated to cover the consultation as well as the medication.
- People who value a dated, versioned telemedicine policy that names the clinical entity behind the prescriptions.
- Anyone who reads batch-testing claims and wants the pharmacopoeia chapters cited by number.
Look elsewhere if
- Anyone who needs a straight answer on coverage. The price page excludes three states and the telemedicine policy says the real list is given at registration.
- Readers who need to know what the price becomes after the first fill. No plan term appears beside either figure.
- Buyers who want the membership question answered. Across six pages the word does not appear.
- Anyone who wants the pharmacy named — the site asks the question itself and answers it behind a control that does not render.
- Readers who want an individual prescriber named.
How this review was verified
- Re-read the homepage, both compounded product pages, the Terms, the Privacy Policy and the telemedicine policy on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller.
- Ran a word-bounded census for membership across all six pages and found zero occurrences in the extracted visible text, which is why the row is recorded as not stating a membership rather than as having none.
- Recorded both coverage statements verbatim and stored no state list, rather than deriving forty-seven states from a three-state exclusion while the seller's own policy says the real list is unpublished.
- Extracted the exclusion footnote from a Python html.parser pass over text nodes only, with residual markup asserted absent, so it is confirmed as rendered text rather than something present only in the markup.
- Noted which content did not render: the FAQ answers, including the seller's own question about FDA-regulated pharmacies, sit behind controls that produce no text. An answer that does not render is not published.
- Printed the status, byte size and effective URL of every fetch and compared the effective path to the requested one, and ran a nonsense path against this host in the same run, which returned 404.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. Neither returned a letter; untitled letters are published separately and were not searched.